Preserving Strong Patents to Ensure Investment in New Therapies
At a time when we need to be creating incentives for investment in innovative therapies, Congress is considering patent reform legislation that could make future advances in treating epilepsy all too rare. A strong and secure patent system that encourages investments in innovative treatments and devices is critical for the millions of Americans waiting for breakthrough therapies and a cure to live their lives to their fullest potential.
Patient Community Supports a Strong Patent System
On September 8, 2015, the Epilepsy Foundation and a diverse group of more than 100 national and state-based advocacy organizations sent a letter to the House and Senate Judiciary Committees urging Congress to amend H.R. 9 to preserve the highly-detailed and sophisticated systems designed by Hatch-Waxman and BPCIA and avoid weakening the patents that sustain medical research. Read the letter here.
Patient Community Expresses Concern over Compulsory Licensing
On October 30, 2018, the Epilepsy Foundation and 30 patient groups, sent letters to the House of Representatives expressing concern over the compulsory licensing provisions included in Represenative Lloyd Doggett's proposed Medicare Negotiation and Competitive Licensing Act of 2018 (H.R. 6505). If passed, this legislation would allow the U.S. government to grant compulsory licenses to generic drug manufacturers, an unprecented act that would bypass the existing patent and exclusivity protections afforded to companies. These provisions threaten to undermine important aspects of our health care system that encourage research and innovation in drug development. Read the letter sent to each Representative here.